Loxapine succinate

A typical antipsychotic agent that displays an extremely strong binding affinity for dopamine D4 and serotonin 5-HT2 receptors.Schizophrenia Approved (In Vitro) :In the presence of Loxapine, [3H]ketanserin binds to 5-HT2 receptor in Frontal cortex of brain in human and bovine with Ki value of 6.2 nM and 6.6 nM, respectively. Loxapine has the rank order of potency for the various receptors appears to be as follows: 5-HT2≥D4>>>D1>D2 in comparing competition experiments involving the human membranes.Loxapine (0-20 μM, 24 h or 72 h) reduces IL-1β secretion by LPS-activated mixed glia cultures, reduces IL-2 secretion in mixed glia cultures, and decreases IL-1β and IL-2 secretion in LPS-induced microglia cultures.Loxapine (4 μM, 24 h) is active against multiple-antibiotic-resistant or Fluoroquinolone-resistant S. Typhimurium.Loxapine (1, 2, 4 and 8 μM) suppresses intracellular Methicillin-resistant S. aureus (MRSA), Y. enterocolitica and S. flexneri in RAW264.7. (In Vivo) :Loxapine (5 mg/kg; i.p.; daily for 4 or 10 weeks) decreases serotonin (S2) but does not elevate dopamine (D2) receptor numbers in the rat brain.

27833-64-3

CL 71,563

Pharmacology & Drug Discovery

>98% (HPLC)

10 mM in DMSO

CN1CCN (CC1) C2=NC3=CC=CC=C3OC4=C2C=C (C=C4) Cl.C (CC (=O) O) C (=O) O

C22H24ClN3O5

445.8961

Storage temperature: -20°C. Stability: ≥ 2 years

For research use only.